List view / Grid view
An assay is an analytical procedure in laboratory medicine, pharmacology and molecular biology for measuring the activity of a target entity.
The emergence of new antibody-based therapeutics, such as antibody-drug conjugates, alongside a continued drive towards alternatives to animal testing approaches, highlights the need for precise and sensitive tools enabling the identification and characterisation of the best drug candidates for clinical progression. Capable of keeping up with the evolving drug development…
Sartorius have published its second edition High-Throughput Screening (HTS) by Cytometry handbook.
Sphere Fluidics have developed the Cyto-Mine® Chroma platform, which provides multiplexing and greater assay flexibility, reducing timelines and cost.
In this four-part series, Dr Raminderpal Singh will discuss the challenges surrounding limited data quality, and some pragmatic solutions. In this second article, he discusses the problems that occur when using data of poor quality.
25 July 2024 | By Eurofins Discovery
Eurofins Discovery’s Luke Oostdyk, PhD, will highlight anti-obesity target combination therapies and cell-based assays ideal for testing functional activity, specificity, potency and signalling mechanisms of desired therapies against multiple disease-relevant targets.
A new assay has been developed which enables the detailing of intact proviral genomes of under-studied HIV strains.
20 June 2024 | By Eurofins DiscoverX
Join this webinar to discover how GPCR functional, cell-based assays determine off-target effects, reveal safety issues, and define drug mechanism of action to ultimately evaluate the therapeutic potential of candidate molecules.
Following Zymeworks’ presentation at AACR 2024, in this Q&A, Dr Nina Weisser explains how the next generation trispecific T cell engager platform with integrated CD28 costimulation is engineered to tackle solid tumours.
In this Q&A, Simon Kerry, CEO of Curve Therapeutics, shares the company’s recent milestones, insights into the innovative Microcycle platform, and how Curve plans to remain on the cutting edge of drug discovery.
A panel of HTS assays was developed using the Transcreener platform to accelerate the development of selective helicase inhibitors.
AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14
In this Q&A, we speak to Dr Emma Murphy, Head of Biology at the Alzheimer’s Research UK Oxford Drug Discovery Institute. Among her many insights, she discusses how the challenges in developing reproducible assays can be addressed, as well as strategies used to translate promising findings into clinically relevant tools…
28 February 2024 | By Eurofins DiscoverX
Watch this webinar to learn about recently published research toward the advancement of non-opioid analgesics targeting the Nav1.8 ion channel, a validated pain target primarily found in peripheral nociceptors.
Researchers found that the D48 antibody neutralised HSV-1 virus infection, which could lead to broad-spectrum drug and vaccine development.
22 February 2024 | By Dr. Reece Gardner
Hear how Dr. Reece Gardner from Curve Therapeutics uses the Dianthus instrument with Spectral Shift technology to validate Microcycle® hits.
